Table 2.
Baseline prevalence rates for Taiwanese adult workers not fulfilling metabolic syndrome (MetS) criteria initially
| 2002 baseline data, divided by MetS outcome in 2007** | ||||
|---|---|---|---|---|
| Abnormality Prevalence* | Overall N = 1384 | Without MetS outcome n = 1209 | With MetS outcome, n = 175 | P |
| MetS component (not segregated) | ||||
| COB | 54 (3.9%) | 28 (2.3%) | 26(14.9%) | <0.01 |
| Hyper-GL | 284 (20.5%) | 234 (19.4%) | 50(28.6%) | 0.01 |
| HBP | 245 (17.7%) | 193 (16.0%) | 52(29.7%) | <0.01 |
| Low-HDL | 338 (24.4%) | 269 (22.2%) | 69(39.4%) | <0.01 |
| Hyper-TG | 190 (13.7%) | 139 (11.5%) | 51(29.1%) | <0.01 |
| MetS component (segregated by count and combination) | ||||
| Single component | 511 (36.9%) | 451 (37.3%) | 60 (34.3%) | 0.44 |
| Hyper-GL alone | 149 (10.8%) | 132 (10.9%) | 17(9.7%) | 0.62 |
| Low-HDL alone | 168 (12.1%) | 151 (12.5%) | 17(9.7%) | 0.27 |
| HBP alone | 115 (8.3%) | 107 (8.9%) | 8(4.6%) | 0.02 |
| Hyper-TG alone | 63 (4.6%) | 51 (4.2%) | 12(6.9%) | 0.19 |
| COB alone | 16 (1.2%) | 10 (0.8%) | 6(3.4%) | 0.07 |
| Two components | 300 (21.7%) | 206 (17.0%) | 94 (53.7%) | <0.01 |
| Low-HDL-plus-Hyper-TG | 61 (4.4%) | 43 (3.6%) | 18(10.3%) | <0.01 |
| Hyper-GL-plus-Low-HDL | 51 (3.7%) | 42 (3.5%) | 9(5.1%) | 0.34 |
| Low-HDL-plus-HBP | 42 (3.0%) | 26 (2.2%) | 16(9.1%) | <0.01 |
| Hyper-TG-plus-HBP | 31 (2.2%) | 22 (1.8%) | 9(5.1%) | 0.05 |
| Hyper-GL-plus-Hyper-TG | 30 (2.2%) | 22 (1.8%) | 8(4.6%) | 0.09 |
| COB-plus-Low-HDL | 16 (1.2%) | 7 (0.6%) | 9(5.1%) | <0.01 |
| COB-plus-HBP | 10 (0.7%) | 5 (0.4%) | 5(2.9%) | 0.06 |
| COB-plus-Hyper-GL | 7 (0.5%) | 5 (0.4%) | 2(1.1%) | 0.38 |
| COB-plus-Hyper-TG | 5 (0.4%) | 1 (0.1%) | 4(2.3%) | 0.05 |
* The abnormality prevalence is demonstrated as numbers and proportions, %. The upper rows are non-segregated distributions of MetS components, one or two risk factors are included and overlapping can happen; the lower rows are segregated by each signal and combinations, all individual conditions are listed. Abbreviations: Hyper-GL, hyperglycemia; Low-HDL, Low-HDL cholesterolemia; HBP, high blood pressure; Hyper-TG, hypertriglyceridemia; COB, central obesity.
**χ2 tests were conducted for categorical variables between groups with/without MetS outcome.